Rheumatology CME

Maximize your CME allowance with MDCalc and get up to a $3,500 bonus gift card of your choice. Earn AMA PRA Category 1 Credits^TM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

Expert Advice and Insightful Commentary

The MKSAP® 19 Audio Companion sheds light on the latest diagnostic approaches, management strategies, and treatment guidelines. In this comprehensive audio CME program, you’ll join host Donald L. Deye, MD, FACP, as he leads lively discussions with esteemed colleagues in 11 internal medicine subspecialties. Listen as experienced clinicians from some of the world’s finest medical institutions share patient stories, insightful views of recent clinical advances, and more.

Anytime, Anywhere Audio CME

With the MKSAP 19 Audio Companion, you get:

• All-new advice and commentary — a reliable, and entertaining way to learn current oncology trends, the latest approaches to diabetes treatment, COVID updates, new tactics for managing patients with COPD, and so much more
• An easy way to prep for your ABIM certification or MOC exam
• Flexible learning to fit your schedule — in your car, between appointments, while you work out
• Companion booklets — high-impact PDF learning aids to quickly review and retain key points (print booklets available for an additional charge)
• The opportunity to earn AMA PRA Category 1 Credits™ and ABIM MOC points
• Four FREE sets of extension questions — a $350 value that brings you incremental AMA PRA Category 1 Credits™ and MOC points

Audience

General internists and primary care physicians; subspecialists who need to remain up to date in internal medicine; residents preparing for the certifying examination in internal medicine; physicians preparing for the recertification examination. 

Learning Objectives

• Discuss the most clinically relevant patient care information in all subspecialties of Internal Medicine based on the medical literature of the last 3 to 5 years
• Describe clinical situations in which this new knowledge will improve the quality of care
• Diagnose disease states that are less common and sometimes overlooked and confusing
• Determine when to refer patients for surgery or care by subspecialists

Rheumatology CME: Expand Your Knowledge

The Brigham Board Review and Comprehensive Update in Rheumatology is designed to improve overall knowledge and clinical competency with comprehensive updates on basic principles, changing guidelines and therapeutic strategies. In this convenient online CME program, world-renowned faculty — led by Jonathan S. Coblyn, MD, Paul F. Dellaripa, MD, and Simon M. Helfgott, MD — cover key rheumatologic medicine topic areas, including:

• Rheumatoid arthritis
• SLE and antiphospholipid AB syndrome
• Sjögren’s and MCTD
• Psoriatic arthritis and other spondyloarthropathies
• Regional pain/sports medicine
• Inflammatory myositis and other myopathies
• Infectious, rheumatologic, and systemic diseases
• and more…

Stay on top of your game with the StatPearls Physician Unlimited CME programs. With 6,046 activities, StatPearls is the largest CME provider in the world. These Pub-Med Indexed articles are categorized into 162 specialty areas which lets you better access activities that will make the biggest impact on your practice. One subscription allows access to all the activities, including all state-requirements.

Pricing Options

• 6 Month subscription: All 6,339 CME Activities – $249 per 6 months
• Annual subscription: All 6,339 CME Activities – $349 per 1 year
• Lifetime: All 6,339 CME Activities + Access to Board Reviews Forever – $1999

Target Audience: Physicians focusing on Allergy, Rheumatology.

Biosimilar drugs are products meant to be similar in quality, safety, and efficacy to an already licensed reference biotherapeutic product. Whereas generics are virtually identical replicas of conventional medications, biosimilars are not the same as the original product – a practically unavoidable outcome because of the considerably large molecular structure that biologics mimic. The literature suggests that learning activities focused on the evolving landscape of biosimilars, which are germane to the therapeutic area because of their potential role in cost containment. Both the FDA and medical literature independently affirm the need for clinician education on biosimilars, including:  comparative efficacy; adverse event rates and management (potential concerns have included immunogenicity); regulatory guidance on interchangeability and substitution – including prescribers retaining some degree of ability to intervene in a product’s substitution at the dispensing stage; and cost considerations.

Target Audience:

The following healthcare professionals: Rheumatologists, gastroenterologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with the inflammatory disease states covered by this activity.

By the end of the session the participant will be able to:

• Describe biosimilar drugs, how they differ from generic drugs, the FDA process for their approval.
• Describe practical considerations the clinician needs when determining whether to consider when deciding whether substituting or allowing the substitution of a biosimilar medication for its reference medication, and apply them to patient case(s).
• Describe how biosimilars for inflammatory health conditions are impacting the treatment landscape with respect to number of treatment options, affordability, and safety considerations.
• Identify the currently available and emerging pharmacotherapeutic treatments for management of inflammatory health conditions and apply them to patient cases using evidence-based medicine.
• Describe strategies for helping patients understand the implications of using biosimilars.